drugset

drugset / Trial / NCT05029063

Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters

NCT05029063 ↗

Phase 3 Recruiting 1828 enrolled Ottawa Hospital Research Institute

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.

Timeline

Start: 2022-10-05
Primary completion: 2026-12
Completion: 2027-12

Publications

Background Ikesaka R, Siegal D, Mallick R, Wang TF, Witham D, Webb C, Carrier M; Canadian Venous Thromboembolism Research Network (CanVECTOR). Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial. Res Pract Thromb Haemost. 2021 May 5;5(4):e12517. doi: 10.1002/rth2.12517. eCollection 2021 May.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivaroxaban	Other / unclassified	10 mg	Oral

Indications